Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer

NCT00546156 is registered in ClinicalTrials.gov with Ian E. Krop, MD, PhD as lead sponsor.

NCT NCT00546156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00546156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Lead sponsor
Ian E. Krop, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
December 31, 2012
Enrollment
104 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer